Adenovirus-mediated human Topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells

Cancer Research

Volumn 59, Issue 18, 1999, Pages 4618-4624

  Zhou, Zhichao ^a   Zwelling, Leonard A ^a   Kawakami, Yasuhiko ^a   An, Taeha ^a   Kobayashi, Kunihisa ^b   Herzog, Cynthia ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SPECIFICITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DETERMINATION; DNA TRANSFER; ENZYME ASSAY; ENZYME SUBUNIT; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033568541     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Harris, A. L., and Hochhauser, D. Mechanism of multi-drug resistance in cancer treatment. Acta Oncol., 31: 205-213, 1992.
2. Osheroff, N. Biochemical basis for the interaction of type I and type II topoisomerases with DNA. Pharmacol. Ther., 41: 233-241, 1989.
3. Zwelling, L. A., Hinds, M., Chan, D., Mayes, J., Sie, K. L., and Parker, E. Characterization of an amsacrine-resistant line of human leukemia cells: evidence for a drug-resistant form of topoisomerase II. J. Biol. Chem., 264: 16411-16420, 1989
4. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
5. Wang, J. C. DNA topoisomerase. Annu. Rev. Biochem., 65: 635-092, 1996.
6. Hinds, M., Deisseroth, K., Mayes, J., Altschuler, E., Jansen, R., Ladley, F. D., and Zwelling, L. A. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of lopoisomerase II. Cancer Res., 51: 4729-4731, 1991.
7. Scheltema, J. M., Romijn, J. C., van Steenbrugge, G. J., Beck, W. T., Schroder, F. H., and Mickisch, G. H. Decreased levels of topoisomerase IIα in human renal cell carcinoma lines resistant to etoposide. J. Cancer Res. Clin. Oncol., 123: 546-554, 1997.
8. Asano, T., An, T., Zwelling, L. A., Takano, H., Fojo, A. T., and Kleinerman, E. S. Transfection of a human topoisomerase IIα gene into etoposide-resistant human breast tumor cells sensitizes the cell to etoposide. Oncol. Res., 8: 101-110, 1996.
9. Asano, T., Zwelling, L. A., An, T., McWatters, A., Herzog, C. E., and Kleinerman, E. S. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumor cell line intrinsically resistant to etoposide. Br. J. Cancer, 73: 1373-1380, 1996.
10. Graham, F. L., and Prevec, L. Manipulation of adenovirus vectors. Gene transfer and expression protocols. In: E. J. Murray (ed.), Methods in Molecular Biology, Vol. 7, pp. 109-128. Clifton, NJ: The Humana Press, 1991.
11. Ali, M., Lemoine, N. R., and Ring, C. J. A. The use of DNA viruses as vectors for gene therapy. Gene Ther., 1: 367-384, 1994.
12. Matsumoto, Y., Takano, H., and Fojo, T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res., 57: 5086-5092, 1997.
13. Fidler, I. J., and Kleinerman, E. S. Selective destruction of allogeneic tumor cells by human blood monocytes activated with liposomes containing lymphokines. J. Clin. Oncol., 2: 937-943, 1984.
14. Zwelling, L. A., Mayes, J., Hinds, M., Chan, D., Altschuler, E., Carroll, B., Parker, E., Deisseroth, K., Radcliffe, A., Seligman, M., Li, L., and Farquhar, D. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug reactions. Biochemistry, 30: 4048-4055, 1991.
15. Kozak, M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res., 15: 8125-8132, 1987.
16. Kobayashi, K., Oka, K., Forte, T., Ishida, B., Teng, B., Ishimura-Oka, K., Nakamuta, M., and Chan, L. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J. Biol. Chem., 271: 6852-6860, 1996.
17. Teng, B., Blumenthal, S., Forte, T., Navaratnam, N., Scott, J., Gotto, A. M., Jr., and Chan, L. Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA-editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production. J. Biol. Chem., 269: 29395-29404, 1994.
18. Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early region 1 and 3. Proc. Natl. Acad. Sci. USA, 91: 8802-8806, 1994.
19. Hitt, M., Bett., A. J., Addison, C. L., Prevec, L., and Graham, F. L. Techniques for human adenovirus vector construction and characterization. In: K. W. Adolph (ed.), Methods in Molecular Genetics: Viral Gene Techniques, Vol. 7, pp. 13-30. San Diego: Academic Press, 1995.
20. Tsai-Pflugfelder, M., Liu, L. F., Liu, A. A., Tewey, K. M., Whang-Peng, J., Knutsen, T., Huebner, K., Croce, C. M., and Wang, J. C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc. Natl. Acad. Sci. USA, 85: 7177-7181, 1988.
21. Fan, D., Poste, G., Ruffoli, R. R., Jr., Dong, Z., Seid, C., Earnest, L. E., Campbell, T. E., Clyne, R. K., Beltran, P. J., and Fidler, I. J. Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzepine. Int. J. Oncol., 4: 789-798, 1994.
22. Zhang, W-W., Fang, X., Mazur, W., French, B. A. Georges, R. N., and Roth, J. K. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther., 1: 5-13, 1994.
23. Zhang, W-W., Koch, P. E., and Roth, J. A. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. BioTechniques, 18: 444-447, 1995.
24. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., and Mirabeli, C. K. Biochemical and pharmacological properties of p170 and p180 form of topoisomerase II. Biochemistry, 28: 8154-8160, 1989.
25. Kaufmann, S. H., McLaughlin, S. J., Kastan, M. B., Liu, L. F., Karp, J. E., and Burke, P. J. Topoisomerase II level during granulocyte maturation in vitro and in vivo. Cancer Res., 51: 3534-3543, 1991.
26. Asano, T., An, T., Mayes, J., Zwelling, L. A., and Kleinerman, E. S. Transfection of human topoisomerase II a into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem. J., 319: 307-313, 1996.
27. Roth, J. A., Swisher, S. G., Merritt, J. A., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., El-Naggar, A. K., Fossella, F. V., Glisson, B. S., Hong, W. K., Khurl, F. R., Kurie, J. M., Nesbitt, J. C., Pisters, K., Putnam, J. B., Schrump, D. S., Shin, D. M., and Walsh, G. L. Gene therapy for non-small cell lung cancer: a preliminary report of a Phase I trial of adenoviral p53 gene replacement. Semin. Oncol., 25: 33-37, 1998.
28. Clayman, G. L., El-Naggar, A. K., Lippman, S. M., Henderson, Y. C., Frederick, M., Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., Roth, J. A., Hong, W. K., Bruso, P., and Goepfert, H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol., 16: 2221-2232, 1998.
29. Towatari, M., Adachi, K., Marunouchi, T., and Saito, H. Evidence for a critical role of DNA topoisomerase IIα in drug sensitivity revealed by inducible antisense RNA in a human leukemia cell line. Br. J. Haematol., 101: 548-551, 1998.
30. Binaschi, M., Farinosi, R., Austin, C. A., Fisher, L. M., Zunino, F., and Capranico, G. Human DNA topoisomerase II a dependent DNA cleavage and yeast cell killing by anthracycline analogues. Cancer Res., 58: 1886-1892, 1998.
31. Elsea, S. H., Osheroff, N., and Nitiss, J. L. Cytotoxicity of quinolones toward eukaryotic cells: identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J. Biol. Chem., 267: 13150-13153, 1992.
32. Reid, R. J., Kauh, E. A., and Bjornsti, M. A. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. J. Biol. Chem., 272: 12091-12099, 1997.
33. McLeoed, H. L., Douglas, F., Oates, M., Symonds, R. P., Prakash, D., Van Der Zee, A. G. J., Kaye, S. B., Brown, R., and Keith, W. N. Topoisomerase I and II activity in human breast, cervix, lung, and colon cancer. Int. J. Cancer, 59: 607-611, 1994.
34. Potmesil, M., Hsiang, Y. H., Liu, L. F., Bank, B., Grossberg, H., Kirschenbaum, S., Forlenzar, T. J., Penziner, A., Kanganis, D., and Knowles, D. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res., 48: 3537-3543, 1988.
35. Guinee, D. G., Holden, J. A., Benfield, J. R., Woodward, M. L., Przygodzki, R. M., Fishback, N. F., Koss, M. N., and Travis, W. D. Comparison of DNA topoisomerase IIα expression in small cell and non-small cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer (Phila.), 78: 729-735, 1996.